Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.4450
Nov 13 • 3:59 PM ET Dollar change-0.1268 Percentage change(-22.18%)
Aftermarket Close
0.4210
Aftermarket • 7:56 PM ET Dollar change-0.0240 Percentage change(-5.39%)
Nov 14, 6:12 AMCuris advances emavusertib PCNSL program toward 2028 filing amid tight cash runway
Index
-
Market Cap
2.97M
Enterprise Value
-1.85M
Income
-21.54M
Sales
1.14M
Book/sh
0.62
Cash/sh
0.83
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
24
IPO
Aug 01, 2000
P/E
-
Forward P/E
-
PEG
-
P/S
2.61
P/B
0.72
P/C
0.53
P/FCF
-
EV/EBITDA
-
EV/Sales
-1.62
Quick Ratio
0.43
Current Ratio
0.43
Debt/Eq
0.29
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-6.37
EPS next Y
-2.54
EPS next Q
-0.81
EPS this Y
-30.55%
EPS next Y
83.23%
EPS next 5Y
6.87%
EPS past 3/5Y
63.80% 45.78%
Sales past 3/5Y
-2.42% -2.71%
EPS Y/Y TTM
91.34%
Sales Y/Y TTM
-90.23%
EPS Q/Q
80.29%
Sales Q/Q
-100.00%
Insider Own
17.07%
Insider Trans
0.00%
Inst Own
8.65%
Inst Trans
-0.22%
ROA
-92.78%
ROE
-693.93%
ROIC
-844.53%
Gross Margin
94.55%
Oper. Margin
-3319.60%
Profit Margin
-1893.15%
SMA20
-22.92%
SMA50
-41.93%
SMA200
-94.54%
Trades
Shs Outstand
6.68M
Shs Float
5.54M
52W High
28.40 -98.43%
52W Low
0.32 36.92%
Volatility
19.52% 28.67%
ATR (14)
0.19
RSI (14)
38.74
Beta
3.24
Rel Volume
0.18
Avg Volume
3.92M
Volume
720,367
Perf Week
-50.91%
Perf Month
-12.40%
Perf Quarter
-75.28%
Perf Half Y
-95.46%
Perf YTD
-97.75%
Perf Year
-98.03%
Perf 3Y
-99.59%
Perf 5Y
-99.98%
Perf 10Y
-99.99%
Prev Close
0.57
Price
0.44
Change %
-22.18%
Consensus
Strong Buy
Avg. Price Target
$25.33
Implied Upside
+5,592.1%
Analysts16incl. previous ratings
Rating Distribution14 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 19, 2025Resumed
HH.C. Wainwright
Buy$17+3,720.2%
Nov 17, 2023Initiated
TFC logoTTruist
Buy$26+5,742.7%
Apr 04, 2022Downgrade
RJF logoRRaymond James
Outperform → Mkt Perform
Oct 13, 2021Initiated
RJF logoRRaymond James
Outperform$15+3,270.8%
Mar 25, 2021Initiated
RILY logoRB. Riley Securities
Buy$19+4,169.7%
Jul 29, 2020Initiated
LLaidlaw
Buy$5+1,023.6%
Jul 17, 2020Initiated
CCantor Fitzgerald
Overweight$4+798.9%
Oct 24, 2017Initiated
GGuggenheim
Buy$7+1,473.0%
Mar 02, 2016Initiated
SSun Trust Rbsn Humphrey
Buy$3+574.2%
Nov 09, 2015Reiterated
RROTH Capital
Buy$6 → $5+1,023.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAITIN KENNETH IDirectorMar 31 '26Buy0.5510,0005,48711,407Apr 01 07:51 AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
PresidentMr. James E. Dentzer
M.B.A.Ms. Diantha Duvall C.P.A.
Chief Development OfficerDr. Jonathan B. Zung Ph.D.
Vice President of Technology Management & Intellectual PropertyMr. Mark W. Noel
Senior Director of Human ResourcesMs. Rachel Blasbalg